Graybug Inc., a spinout of Johns Hopkins University's Wilmer Eye Institute that's developing an experimental microparticle drug for wet age-related macular degeneration, has closed a $1.74 million series A2 financing to help advance a preclinical drug and further prove its sustained-release technology.